Mayo Clinic and Stanford Develop AI-Driven Blood Test to Enhance Cancer Treatment Predictions
Researchers from Mayo Clinic and Stanford Medicine have developed a groundbreaking blood test that maps the tumor microenvironment, offering a more precise method to predict patient responses to immunotherapy. This innovation, published in Nature, marks a significant advancement in precision oncology. The test utilizes artificial intelligence to analyze methylation patterns on cell-free DNA from tumors, allowing for a detailed understanding of the tumor's spatial ecotypes. This approach provides insights into the tumor's immune and stromal environments, which are crucial for determining treatment efficacy. The study involved over 1,300 patients with various cancers, including melanoma, lung, and bladder cancers, demonstrating the test's potential to improve treatment decisions and patient outcomes. 
